RxDoctor Payments Data

Jennifer Herbert, MD

Family Medicine · Grovetown, GANPI 1417077355

Payments from drug & device makers

$17,162in general payments, 2019–2025

Across 1,141 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • AbbVie$2K
  • Amgen$2K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Boehringer Ingelheim$673
  • plus $6K from 45 others

What the payments were for

  • Food & beverage$17,095100%
  • Education$670%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,162 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$58,728
Medicare patients
195
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$160,630
EliquisApixaban65$80,313
MounjaroTirzepatide75$75,746
JardianceEmpagliflozin40$43,702
RybelsusSemaglutide20$28,834
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$23,350
Synjardy XrEmpagliflozin/Metformin Hcl26$20,247
FarxigaDapagliflozin Propanediol13$14,459
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$13,598
Repatha SureclickEvolocumab14$10,913
Soliqua 100-33Insulin Glargine/Lixisenatide11$9,023
LivaloPitavastatin Calcium16$7,192
SynthroidLevothyroxine Sodium41$4,892
Vilazodone Hcl15$3,033
Valsartan92$2,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,838$189,464151 claims
PfizerEliquis$1,347$80,31365 claims
Lilly USA, LLCMounjaro$1,366$75,74675 claims
Boehringer IngelheimJardiance, Synjardy Xr$673$63,94966 claims
GSKTrelegy Ellipta, Anoro Ellipta$509$36,94864 claims
AstraZenecaFarxiga$624$14,45913 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$129$9,02311 claims
Kowa Pharmaceuticals America, Inc.Livalo$39$7,19216 claims
AbbVieSynthroid$1,962$4,89241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Grovetown

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →